{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GVHD%2CAcute", "query": { "condition": "GVHD,Acute" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9111, "total_pages": 912, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GVHD%2CAcute&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T11:30:46.891Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02974010", "title": "Sequential Therapy for the Treatment of Severe Bipolar Depression.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bipolar Depression", "Suicidal Ideas", "Suicidal Ideation", "Suicide, Attempted" ], "interventions": [ { "name": "NRX-101 Oral Capsule", "type": "DRUG" }, { "name": "Lurasidone Oral Capsule", "type": "DRUG" }, { "name": "Ketamine Intravenous Infusion", "type": "DRUG" }, { "name": "Saline Solution Intravenous Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeuroRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 22, "start_date": "2018-01-15", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974010" }, { "nct_id": "NCT04518410", "title": "ACTIV-2: A Study for Outpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus", "Covid19" ], "interventions": [ { "name": "bamlanivimab 7000mg", "type": "BIOLOGICAL" }, { "name": "BRII-196+BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IV)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (IM)", "type": "BIOLOGICAL" }, { "name": "SNG001", "type": "DRUG" }, { "name": "Camostat", "type": "DRUG" }, { "name": "BMS-986414 + BMS-986413", "type": "BIOLOGICAL" }, { "name": "SAB-185 (3,840 Units/kg)", "type": "BIOLOGICAL" }, { "name": "SAB-185 (10,240 Units/kg)", "type": "BIOLOGICAL" }, { "name": "CASIRIVIMAB + IMDEVIMAB", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 7000mg", "type": "DRUG" }, { "name": "Placebo for Bamlanivimab 700mg", "type": "DRUG" }, { "name": "Placebo for BRII-196+BRII-198", "type": "DRUG" }, { "name": "Placebo for SNG001", "type": "DRUG" }, { "name": "Placebo for Camostat", "type": "DRUG" }, { "name": "Placebo for SAB-185 (low dose)", "type": "DRUG" }, { "name": "Placebo for BMS-986414 + BMS-986413", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IV)", "type": "DRUG" }, { "name": "Placebo for AZD7442 (IM)", "type": "DRUG" }, { "name": "Placebo for SAB-185 (high dose)", "type": "DRUG" }, { "name": "bamlanivimab 700mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4044, "start_date": "2020-08-19", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 207, "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518410" }, { "nct_id": "NCT05439460", "title": "Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Phenylephrine", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "Arginine Vasopressin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 15, "start_date": "2012-01", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2022-08-05", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05439460" }, { "nct_id": "NCT02494882", "title": "Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 12, "start_date": "2015-06-29", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02494882" }, { "nct_id": "NCT03019523", "title": "The Effect of a Caffeine Blend on Reaction Time, Mental Performance and Focus in Athletic Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mental Fatigue" ], "interventions": [ { "name": "Caffeine Blend", "type": "DIETARY_SUPPLEMENT" }, { "name": "Sugar Pill", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Mary Hardin-Baylor", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "25 Years", "sex": "MALE", "summary": "18 Years to 25 Years · Male only" }, "enrollment_count": 31, "start_date": "2016-08", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2017-01-25", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "Belton, Texas", "locations": [ { "city": "Belton", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019523" }, { "nct_id": "NCT02974959", "title": "Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Traumatic Brain Injury", "Acute Brain Injuries" ], "interventions": [ { "name": "gammaCore active device", "type": "DEVICE" }, { "name": "gammaCore sham device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "CentraCare", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 14, "start_date": "2016-10", "completion_date": "2020-11", "has_results": false, "last_update_posted_date": "2021-02-04", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02974959" }, { "nct_id": "NCT00075959", "title": "Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intracerebral Hemorrhage" ], "interventions": [ { "name": "NXY-059", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2004-08", "completion_date": "2006-01", "has_results": false, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 61 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00075959" }, { "nct_id": "NCT06172803", "title": "Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Long Covid19", "Exercise Intolerance", "Riboflavin-Responsive" ], "interventions": [ { "name": "Restoring Energy with Sub-symptom Threshold Aerobic Rehabilitation Exercise", "type": "BEHAVIORAL" }, { "name": "Light Stretching/Breathing Exercises", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 4, "start_date": "2023-10-01", "completion_date": "2024-01-15", "has_results": false, "last_update_posted_date": "2024-06-06", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172803" }, { "nct_id": "NCT00058461", "title": "Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-cell Childhood Acute Lymphoblastic Leukemia", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "L3 Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma" ], "interventions": [ { "name": "ifosfamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 82, "start_date": "2003-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-10-08", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058461" }, { "nct_id": "NCT01246622", "title": "Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Recurrent Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cytarabine", "type": "DRUG" }, { "name": "lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2011-02-07", "completion_date": "2019-06-05", "has_results": false, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-06-26T11:30:46.891Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01246622" } ] }